milvexian
bms
['axiomatic', 'fxi']
#phri scientist at #esccongress tomorrow presents on axiomatic-ssp
rationale and design of the phase ii trial
antithrombotic treatment with fxia inhibition to optimize management of acute thromboembolic events for secondary #strokeprevention 
Global Health. Global Partnerships. Global Impact. Birthplace of 9 most measurable modifiable risk factors for #heartdisease & #stroke. @McMasterU @HamHealthSci